Lipoprotein subclasses compensate the classic atherogenic lipid profile of women with polycystic ovary syndrome, but common antiandrogenic treatments worsen their lipidome
Abstract
OBJECTIVES: Patterns of circulating inflammatory glycoproteins and lipoprotein subclasses are not well-defined in polycystic ovary syndrome (PCOS). We aimed to describe these profiles and effects of drug intervention on those parameters.
DESIGN: Cross-sectional and longitudinal interventional prospective studies.
METHODS: The cross-sectional study included 340 patients with PCOS and 92 non-hyperandrogenic women. Glycoprotein and lipoprotein profiles were measured by proton-nuclear magnetic resonance spectroscopy. We also analyzed their changes after treatment with metformin, an oral contraceptive, or an oral contraceptive plus spironolactone in 13, 20, and 16 women with PCOS, respectively.
RESULTS: Circulating glycoproteins were increased in obese women, regardless of PCOS. PCOS-associated increased VLDL-cholesterol and VLDL-triglycerides, but reduced HDL-cholesterol, HDL-triglycerides, IDL-triglycerides, LDL-cholesterol, and LDL-triglycerides, compared with controls. Regarding lipoprotein particles (P), PCOS patients had higher large and medium VLDL-P and, accordingly, larger VLDL sizes than controls. Interestingly, women with PCOS also showed larger HDL-P and HDL sizes than controls, a pattern that is not associated with cardiovascular disease. However, large and medium LDL-P were reduced in patients. Circulating glycoproteins increased with all treatments. Antiandrogenic regimens induced a larger increase in HDL-cholesterol, HDL-triglycerides, IDL-triglycerides,…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 340 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.